[EN] C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY [FR] COMPOSÉS C-ARYL GLYCOSIDES POUR LE TRAITEMENT DU DIABÈTE ET DE L'OBÉSITÉ
Procédé de préparation de perhalogénoalkylthioéthers
申请人:RHONE-POULENC AGROCHIMIE
公开号:EP0374061A1
公开(公告)日:1990-06-20
Procédé de préparation de perhalogenoalkylthioéthers dans lequel on met en contact, éventuellement dans un solvant
- un réducteur formé d'un métal choisi parmi le zinc, le cadmium, l'aluminium, le manganèse, avec du dioxyde de soufre, ou formé d'un dithionite alcalin ou d'un hydroxyméthane sulfinate alcalin, alcalino terreux ou métallique, ou formé d'un anion formiate et le dioxyde de soufre,
- un disulfure
- un halogénure de perfluoroalkyle.
Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of MGLUR2 receptors
申请人:Janssen Pharmaceutica NV
公开号:US10005786B2
公开(公告)日:2018-06-26
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I)
as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors
申请人:Janssen Pharmaceutica NV
公开号:US10005785B2
公开(公告)日:2018-06-26
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I)
as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.